(TVRD)
NCM – Real Time Price. Currency in USD
3.17
-0.16 (-4.80%)
At close: Mar 27, 2026, 4:00 PM EDT
3.17
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
3.17
-0.16 (-4.80%)
At close: Mar 27, 2026, 4:00 PM EDT
3.17
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
| Name | Position |
|---|---|
| Dr. Imran Alibhai Ph.D. | CEO & Director |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of R&D |
| Dr. John Kauh M.D. | Chief Medical Officer |
| Dr. Michael T. Lewis Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
| Mr. Dan Conn J.D., M.B.A. | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-06 | 8-K | tm268178d1_8k.htm |
| 2026-01-16 | 8-K | tm263373d1_8k.htm |
| 2025-12-18 | 8-K | tm2533917d1_8k.htm |
| 2025-11-19 | 8-K | tm2531635d1_8k.htm |
| 2025-10-20 | S-8 | tm2515908d6_s8.htm |
| 2025-10-14 | 8-K | tm2528638d1_8k.htm |
| 2025-10-07 | S-1/A | tvrd-20250630xs1a.htm |
| 2025-08-14 | 8-K | tm2523431d1_8k.htm |
| 2025-07-14 | 8-K | tm2520679d1_8k.htm |
| 2025-06-09 | 8-K | tm2517442d1_8k.htm |
| Mr. David J. Tweardy M.D. |
| Co-Founder & Scientific Advisory Board Member |
| Mr. Stephen O'Brien CPA | VP of Finance & Corporate Controller |
| Mr. Wallace Hall | Founder, President & Director |